Kornimate/medical-research-clean huggingface dataset:
alar batten graft vs latera for nasal valve collapse

Conditions: Nasal Valve Incompetence

Summary: nasal obstruction is a common complaint for the patient presenting to the otolaryngologist and/or the facial plastic surgeon. there are numerous potential causes of nasal obstruction, with more easily addressed pathologies such as posterior septal deviation and inferior turbinate hypertrophy often being over-diagnosed. nasal valve obstruction, particularly dynamic nasal sidewall collapse, is of significant interest to the rhinoplasty surgeon. traditionally, collapse of the nasal sidewall has been addressed via structural cartilage grafting, with alar batten grafting being the most commonly used method to provide support to the weak nasal sidewall. recently, an absorbable nasal implant, comprised of a polylactic acid copolymer, has been advocated for supporting the nasal sidewall and relieving nasal obstruction. there are several proposed advantages of the implant over traditional operative techniques, namely the ease of endonasal insertion, which can be performed in the outpatient clinic setting. preliminary investigations demonstrate subjective improvement in nasal obstruction with use of the implant, however, there has been no direct comparison with traditional techniques utilizing cartilage grafting. this study is being done at both uva and in oregon. this prospective study will randomize patients with nasal obstruction and documented dynamic nasal sidewall collapse into one of two groups undergoing treatment with either endonasal batten grafting or the absorbable latera nasal valve implant. preoperative and postoperative nasal obstruction will be assessed with a validated survey for nasal obstructive symptoms, the nasal obstruction symptom evaluation (nose) score. the mean preoperative and postoperative nose score between the groups will be compared at 1, 6, 12, and 24 months post-operatively to compare the efficacy of both techniques. subjects will be blinded to the surgical intervention they receive.


Eligibility criteria:
inclusion criteria: * documented physical exam findings of septal deviation * bilateral nasal sidewall collapse on inspiration * subjective improvement in nasal obstruction with use of the modified cottle maneuver exclusion criteria: * prior septorhinoplasty * obvious trauma to the nose causing nasal obstruction * inflammatory conditions such as chronic rhinosinusitis with nasal polyposis * patients using chronic topical nasal decongestants or illicit intranasal drug use * prisoners, cognitively impaired, non-english speaking subjects
an observational study of current practice pattern on the treatment of women with metastatic breast cancer whose tumors overexpress her2neu

Conditions: Breast Cancer

Summary: the purpose of this study is to observe clinical outcomes of metastatic breast cancer patients whose tumors overexpress the her2neu protein and are being treated with trastuzumab (herceptin)either alone or combination with chemotherapy or hormonal therapy.

in clinical practice, patients with metastatic breast cancer are being treated either with trastuzumab alone or trastuzumab in combination with chemotherapy or hormonal therapy as it has shown to increase survival. there is currently minimal information as to how long trastuzumab should be given after disease progresses on trastuzumab. this study is a chart review of the above-mentioned population which will capture information such as; * what chemo or hormonal therapies are chosen by clinicians for her-2 positive metastatic patients to combine with trastuzumab * what the number of treatment regimens are (chemo or hormonal) given with trastuzumab * what the clinical outcome of patients treated is * what happens to the patients cardiac status with long term administration of trastuzumab * what treatment patterns exist in the management of central nervous system metastases this study aims to generate a hypotheses that can be tested from the information collected after is has been analyzed to give clinicians further meaningful data to guide treatment decisions beyond treatment progression.

Eligibility criteria:
inclusion criteria: * patients must have metastatic breast cancer * tumor must have been determined to be her-2 positive 3+ by immunohistochemistry or gene-amplified by fluorescence-in-situ hybridization (fish) * must have received trastuzumab alone or in combination with chemotherapy or hormonal therapy * must not have received trastuzumab in the adjuvant or neoadjuvant setting * must have started trastuzumab treatment for metastatic disease any time between january 1996 to june 2003 exclusion criteria: * patients who received trastuzumab prior to 1996

Keywords: metastatic breast cancer her2neu trastuzumab
motor evoked potential in the affected upper limb predicts the potential of motor recovery in subacute stroke patients

Conditions: Stroke, Subacute

Summary: stroke is the third common cause of adult disability in dveloped countries. early identification of the potential for motor recovery is important to avoid 'learned disuse' and to initiate appropriate therapy with achievable goals. the current cohort study focuses on those patients with safe \<8 and using motor evoked potentials (meps) to improve on prognostication of upper limb motor recovery among subacute stroke patients in a local stroke population.


Eligibility criteria:
inclusion criteria: * first stroke with hemiparesis or hemiplegia with safe \<8 exclusion criteria: * contra-indication to tms or mri, history of seizure, pregnancy and mentally unfit to understand the consent
promoting health in pregnancy and postpartum

Conditions: Obesity; Pregnancy; Overweight

Summary: the purpose of this study is to examine the impact of a lifestyle intervention on gestational weight gain, postpartum weight loss, and other secondary outcomes relative to a usual care control group.

our study will address the following specific aims: (1) examine the impact of a lifestyle intervention on gestational weight gain and postpartum weight loss in overweight and obese women, (2) examine the impact of the intervention on physical activity (pa), dietary intake, and quality of life (qol), (3) examine race differences in total gestational weight gain, pa, dietary intake, and qol; and (4) examine the impact of the intervention on offspring adiposity.

Eligibility criteria:
inclusion criteria: * white or african american woman * overweight or obese (prepregnancy bmi: 25-45 kg/m2) * ≤ 16 wks gestation at screening * age 18-44 years * no plan to move out of the greater columbia area in next 18 months * regular and consistent telephone access * availability for telephone calls * willing to accept random assignment exclusion criteria: * uncontrolled hypertension * fetal anomaly * taking insulin for diabetes * uncontrolled or untreated thyroid disease * mental health or substance-abuse hospitalization in last 6 months * multiple gestation * persistent bleeding in the first trimester * history of more than 3 miscarriages * history of an eating disorder or current eating disorder * history of an incompetent cervix * physical disability that prevents exercise * told by health care provider not to exercise * any other medical conditions that might be a contraindication to exercise or dietary change

Keywords: gestational weight gain lifestyle intervention pregnancy postpartum physical activity nutrition
beta-2 polymorphisms and beta receptor selectivity

Conditions: Heart Failure

Summary: we hypothesize that b2 adrenergic polymorphisms affect b-receptor selectivity in patients with heart failure treated with either a b1-selective or a b-nonselective agent. b-2 polymorphisms may contribute to differing responses to drug treatment with beta-blockers in heart failure. characterizing these polymorphisms may help explain the variability in the degree of "selectivity" of action of b-blockers at the b receptor, namely if their action is specific for the b-1 or b-2 receptor. part a was conducted at the university of utah, and all subjects completed study related activities. part b (sub-study) consists of genotyping of blood samples collected in part a, which will be completed at the university of wisconsin. sub-study (samples and dna isolation) or part b entailed analyzing an extra 10 ml of blood that was taken for dna isolation. genotyping (i.e. determination of genetic makeup) of beta adrenergic polymorphisms utilized polymerase chain reaction followed by pyrosequencing.


Eligibility criteria:
inclusion criteria: * systolic dysfunction with ejection fraction ≤40% * symptomatic heart failure class 2-3 * \>18 years of age * optimal medical therapy of hf excluding the use of any beta-blockers within the previous 30 days of the study exclusion criteria: * active myocarditis * hemodynamically significant valvular heart disease * hypertrophic cardiomyopathy * contra-indications to beta-blockers * concomitant use of beta-agonists * beta-antagonist or anti-arrhythmics * unstable angina * myocardial infarction or bypass surgery within 3 months * significant renal insufficiency \[creatinine \>2.5 mg/dl\], liver disease, or anemia
behavior addictions improvement in parkinson disease's patients treated by subthalamic stimulation : long term follow-up

Conditions: Parkinson Disease

Summary: improvement of behavioral addictions in stn-dbs in pd: long term follow-up

whereas subthalamic nucleus (stn) stimulation is considered an established treatment for motor symptoms in advanced parkinson's disease (pd), its behavioral and psychiatric effects are strongly debated, with some studies showing a worsening or new onset of behavioral and psychiatric issues after stn stimulation and other showing an improvement. however, these data are based mainly on case reports and retrospective series. recently, the investigators group has conducted a prospective study assessing behavior and psychiatric symptoms in patients undergoing stn stimulation up to one year after surgery. after subthalamic stimulation non-motor fluctuations improved and pathologic hyperdopaminergic syndrome, i.e. behavioral addictions (including pathological gambling, hypersexuality, binge eating, compulsive shopping, ...), compulsive use of dopaminergic treatment and dopaminergic dysregulation syndrome (defined as the association of one or more behavioral addictions to compulsive use of dopaminergic treatment), disappeared. these findings represent a milestone because, if confirmed, the indications of stn stimulation might be extended beyond motor complications. to date, there are several long-term studies on motor and cognitive effects of stn stimulation, whereas no long-term longitudinal data on neuropsychiatric effects do exist. therefore, the investigators designed a long-term prospective study, assessing over 3-8 years behavioral and psychiatric effect in the same cohort of patients included in the one-year study. this study will allow to better evaluate the change in non-motor fluctuations and of behavioral issues in the long-term with a standard management.

Eligibility criteria:
inclusion criteria: * patients included in the protocol 'apathy' exclusion criteria: * na

Keywords: parkinson disease deep brain stimulation behavior and psychiatric symptoms improvement
metasarc: patterns of care and outcomes in metastatic soft tissue sarcoma

Conditions: Sarcoma; Metastases; Chemotherapy

Summary: well-designed observational studies of individuals with rare tumors are needed to improve patient care, clinical investigations, and the education of healthcare professionals. the patterns of care, outcomes, and prognostic factors of a cohort of 2225 patients with metastatic soft tissue sarcomas who were diagnosed between 1990 and 2013 and documented in the prospectively maintained database of the french sarcoma group will be analyzed with a focus on : number/frequency of systemic treatments per patient, number/frequency of patients with locoregional treatment of the metastasis, number/frequency of patients with chemotherapy, number/frequency of patients with an off-label drug. outcome (time-to-next treatment \[tnt\] and overall survival \[os\]) will be reported according to histological subtype, as well as the association between tnt and os. prognostic factors of os will be investigated.


Eligibility criteria:
inclusion criteria: * advanced soft tissue sarcoma * age \> 18 exclusion criteria: -

Keywords: outcome time to next treatment overall survival patterns of care
dental care and initiation of anti-osteoporotic therapy

Conditions: Dental Condition; Osteoporosis

Summary: the initiation of bisphosphonate therapy for osteoporosis requires an assessment of the oral status to prevent the risk of osteonecrosis of the jaw. this recommendation is sometimes a hindrance to the initiation of treatment or may be responsible for a delay in treatment or even the failure to initiate treatment. however, in the case of a severe osteoporotic fracture (femoral or humeral neck fracture, vertebral fracture or pelvic fracture), treatment must be rapid because of the major risk of refracture in the short term (multiplied by 5 in the 2 years following the fracture). in the rheumatology department of the nice university hospital, the investigator team take care of patients with osteoporotic fractures either directly in hospital or referred by the orthopedics department as part of a care program. for these patients, the team perform an etiological assessment, bone densitometry and evaluation of the oral status with dental panoramic and tele-expertise to determine if there is an indication to perform surgical care before starting the treatment. therefore, the investigator aimed to describe the number of patients requiring dental surgery befor the initiation of bisphosphonate or denosumab treatment before to introduce treatment for osteoporosis


Eligibility criteria:
inclusion criteria: * osteoporotic fracture requiring treatment with bisphosphonate or denosumab exclusion criteria: * osteoporotic fracture requiring teriparatide treatment
sleep disorders, chronotype, and functional impairment in the restrictive adhd phenotype

Conditions: Attention Deficit Disorder With Hyperactivity; Sleep Disorders, Circadian Rhythm; Quality of Life; Morningness Eveningness Preference

Summary: this study aims to explore chronotype and sleep disturbances in adhd subtypes and their relation to functional impairment.

the goal of this observational study is to compare morningness-eveningness and sleep disturbances between children diagnosed with restrictive adhd (adhd-r) and those with predominantly inattentive adhd (adhd-pi), and to examine how these sleep-related features impact functional impairment.the main question it aims to answer is:are chronotype differences and sleep disturbances associated with greater functional impairment in children with adhd-r compared to adhd-pi and typically developing peers?

Eligibility criteria:
inclusion criteria: * age between 7 and 12 years * willingness to participate in the study with provided consent * diagnosis of adhd according to the schedule for affective disorders and schizophrenia for school-age children - present and lifetime version - turkish adaptation (k-sads); no comorbid psychiatric diagnosis (except oppositional defiant disorder) * presence of 6 or more inattention symptoms accompanied by 5 or fewer hyperactivity/impulsivity symptoms on the disruptive behavior disorders rating scale based on diagnostic and statistical manual of mental disorders-iv * no psychotropic medication use in the past 3 months exclusion criteria: * families who do not consent to participate in the study * children and adolescents with chronic medical conditions and/or currently taking any medications * children and adolescents with intellectual disability (mental retardation) * children and adolescents with comorbid psychiatric diagnoses * presence of a neurological disorder * history of head trauma

Keywords: adhd subtypes, restrictive adhd, sleep disorders, functionality, morningness eveningness preference
a study of ly3549492 in japanese participants with type 2 diabetes mellitus (t2d) and healthy japanese participants

Conditions: Healthy; Type 2 Diabetes Mellitus (T2D)

Summary: the purpose of this study is to evaluate how well ly3549492 is tolerated and what side effects may occur in japanese participants with type 2 diabetes mellitus (t2d) and healthy japanese participants. the study drug will be administered orally. blood tests will be performed to check how much ly3549492 gets into the bloodstream and how long it takes the body to eliminate it. the study will last up to approximately 19 weeks for both part a (cohorts 1-3) for multiple-ascending doses (mad), and part b (cohorts 4-5) multiple-ascending doses (mad), for a total of approximately 25 weeks, including screening.


Eligibility criteria:
inclusion criteria: part a: * participants with t2dm for at least 6 months * with an hba1c value: * equal to or greater than 7.0% and equal to or less than 10.0% at screening for participants treated with diet and exercise alone, or * equal to or greater than 6.5% and equal to or less than 9.0% for participants prior to washout of antidiabetic medications * have had a stable weight for the 3 months prior to screening. stable weight is defined as less than 5% body weight change part b: * have safety laboratory test results within normal reference range for the population or investigative site, or results with acceptable deviations that are judged to be not clinically significant by the investigator. laboratory tests may be repeated if there is a documented technical error, or once at the discretion of the investigator for any out-of-range results exclusion criteria: * have a known clinically significant gastric emptying abnormality * have a 12-lead electrocardiogram (ecg) abnormality * have an abnormal blood pressure or pulse rate * have a significant history within the past 6 months or current evidence of comorbidities capable of altering the absorption, metabolism, or elimination of drug. or constituting a risk when taking the study drug * have a history of chronic medical conditions involving the heart, liver, or kidneys

Keywords: glucose metabolism disorders metabolic diseases endocrine system diseases diabetes mellitus diabetes mellitus, type 2
six month clinical research study for patients with moderate or severe dry eye syndrome

Conditions: Keratoconjunctivitis Sicca; Sjogren's Syndrome; Lupus Erythematosus, Systemic; Arthritis, Rheumatoid; Scleroderma, Systemic

Summary: a six-month clinical research trial to evaluate the effectiveness of an investigational medication for the treatment of dry eye syndrome in patients that have been diagnosed with moderate to severe dry eye syndrome, an autoimmune disorder and/or females 65 years of age or older.


Eligibility criteria:
* eighteen years or older * diagnosis of moderate to severe dry eyes for at least 6 months and meet one or all of the following criteria: * diagnosis of autoimmune disorder * female 65 years of age or older

Keywords: dry eyes rheumatoid arthritis lupus sjogren's syndrome myositis scleroderma autoimmune disorder
a study to investigate the regional brain kinetics of brain drug transporters using p-glycoprotein and breast cancer resistance protein substrates and by using the positron emission tomography ligand 11c-jnj-63779586 in the human brain

Conditions: Alzheimer Disease

Summary: the purpose of this study is to investigate the total body biodistribution and radiation dosimetry of 11c-jnj-63779586 by positron emission tomography (pet) in healthy young adult males (part a); to estimate and compare the uptake, distribution, and clearance of 11c-jnj-63779586 in the brain by pet between mild alzheimer disease (ad) participants (males/females) and age- and gender-matched control participants (part b), corrected for regional cerebral blood flow differences; and to model the tissue specific kinetics of 11c-jnj-63779586 in human brain with the appropriate input function (if) (part b).


Eligibility criteria:
inclusion criteria: part a * healthy men between 18 and 55 years of age, inclusive * body mass index (bmi) between 18 and 30 kilogram per meter square (kg/m\^2) ², inclusive, and a body weight of not less than 50 kilogram (kg) part b * men or women with mild alzheimer's disease (ad), age- and gender-matched control participants, between 55 and 85 years of age, inclusive * bmi between 18 and 35 kg/m\^2, inclusive, and a body weight of not less than 50 kg * mild ad participants will be amyloid positive and have a mini-mental state examination (mmse) greater than or equal to (\>=) 20. the matched control participants will be amyloid negative and have a mmse \>= 26, respectively exclusion criteria: * history of or current clinically significant medical illness including (but not limited to) cardiac arrhythmias or other cardiac disease, hematologic disease, coagulation disorders (including any abnormal bleeding or blood dyscrasias), lipid abnormalities, significant pulmonary disease, including bronchospastic respiratory disease, diabetes mellitus, hepatic or renal insufficiency (estimated glomerular filtration rate \[egfr\] within the screening period of less than 60 millilitre per minute per 1.73 meter square \[ml/min/1.73 m\^2\], thyroid disease, neurologic or psychiatric disease, infection, or any other illness that the investigator considers should exclude the participant or that could interfere with the interpretation of the study results * clinically significant abnormal values for hematology, clinical chemistry, or urinalysis at screening or at admission to the study center as deemed appropriate by the investigator * participant has a clinically relevant abnormal physical- or neurological examination, vital signs or 12-lead electrocardiogram (ecg) * participant has a history of epilepsy or fits or unexplained black-outs other than vasovagal collapse within 10 years before screening * participant has past or planned exposure to ionizing radiation that in combination with the planned administration with the study positron emission tomography (pet) ligand and computerized tomography (ct) scan would result in a cumulative exposure that exceeds local recommended exposure limits